Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP-01
- Development stage
- Preclinical
- Lead developer
- CNBX Pharmaceuticals
- Modality
- Small Molecules
01
Overview
NP-01 is an early-stage drug candidate being developed by CNBX Pharmaceuticals (formerly Cannabics Pharmaceuticals) for the treatment of unspecified neuropsychiatric indications. While the developer is primarily known for its work with cannabinoid-based therapies in oncology, NP-01 represents an expansion into the neuropsychiatric space. According to company filings, the candidate utilizes psychedelic-inspired molecules or cannabinoid-based formulations to address mental health disorders. The program was initiated around 2021 and remains in the early discovery or evaluation phase, with specific molecular targets, biological mechanisms, and chemical structures not yet publicly disclosed.
Beyond the preview
Go deeper on NP-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP-01.